Shanghai and San Francisco Bay Area-based HanchorBio has already taken HCB101, an engineered SIRPα-IgG4 Fc fusion protein, into phase 2 trials for solid tumors and hematologic malignancies, including ...

Apple Tree Partners’ life sciences venture fund has filed litigation against its controlling limited partners, claiming the ...

AbbVie is on board with the idea. The Big Pharma will pay up to $2.1 billion in cash at closing to acquire Capstan. In return ...

Back in 2021, Amgen picked up the phase 3-ready candidate in a $1.9 billion acquisition of Five Prime Therapeutics. The ...

XtalPi has accrued a number of Big Pharma partners over the years, including Eli Lilly, which struck a $250 million deal in 2023 to use XtalPi’s tech to identify potential drug candidates that Lilly ...

The latest phase 3 win is a boost for Moderna’s attempts to create a flu/COVID combination vaccine. The company withdrew a filing for FDA approval for its combo candidate last month while it waited ...

Pliant Therapeutics has terminated its idiopathic pulmonary fibrosis (IPF) program after digging into the increased rate of ...

Cosmo Pharmaceuticals aims to make the colonoscopy a little more up close and personal, for providers anyway, by connecting ...

The FDA is shutting the door to imports of certain endoscope hardware manufactured by Olympus, saying that a production site ...

Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage ...

Embattled CytoDyn and key ex-executives must face an investor lawsuit claiming the company knowingly misled shareholders ...

Bayer-owned BlueRock Therapeutics is laying off 50 employees and shuttering its research labs in Cambridge, Massachusetts, in ...